Inventor · disambiguated record
Mark Albertella
Also filed as: ALBERTELLA MARK · ALBERTELLA MARK R · ALBERTELLA MARK ROBERT
4 granted patents·6 pending applications·4 citations·filing 2017–2024
64Inventor score
Top patents by PatentIndex Score
10 records- 0183US10456413B2Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabineMEDIVIR AB·Filed 2017·Granted Oct 29, 2019·2 cites·20 claims
- 0276US12303521B2Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-PD1 or anti-PDL1 monoclonal antibodyMEDIVIR AB·Filed 2020·Granted May 20, 2025·1 cites·18 claims
- 0373US12479870B2Base-modified cytidine nucleotides for leukemia therapyMEDIVIR AB·Filed 2024·Granted Nov 25, 2025·0 cites·17 claims
- 0472US10960017B2Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination therapy for liver cancerMEDIVIR AB·Filed 2019·Granted Mar 30, 2021·1 cites·15 claims
- 0551US2025213556A1Combination therapy for treating cancerASTRAZENECA AB·Filed 2023·Application pending·0 cites
- 0649US2025228847A1Combination therapy for treating cancerASTRAZENECA AB·Filed 2023·Application pending·0 cites
- 0749US2025235448A1Combination therapy for treating cancerASTRAZENECA AB·Filed 2023·Application pending·0 cites
- 0846US2021261584A1Base-Modified Cytidine Nucleotides for Leukemia TherapyMEDIVIR AB·Filed 2019·Application pending·0 cites
- 0945US2024277715A1Combination therapies comprising a mettl3 inhibitor and a further anticancer agentSTORM THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1039US2020009135A1Therapeutic applications of malt1 inhibitorsMEDIVIR AB·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Albertella files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →